Full Text
Relapse Rates and Symptom Management Among Patients Receiving Natalizumab and other Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis

Abstract

Authors

L Lee J Pike J Kendter D Campagnolo E Jones S Naoshy

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×